[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR082806A1 - Composicion farmaceutica estable - Google Patents

Composicion farmaceutica estable

Info

Publication number
AR082806A1
AR082806A1 ARP110103162A ARP110103162A AR082806A1 AR 082806 A1 AR082806 A1 AR 082806A1 AR P110103162 A ARP110103162 A AR P110103162A AR P110103162 A ARP110103162 A AR P110103162A AR 082806 A1 AR082806 A1 AR 082806A1
Authority
AR
Argentina
Prior art keywords
water
similar structural
pharmaceutical composition
insoluble
active ingredient
Prior art date
Application number
ARP110103162A
Other languages
English (en)
Inventor
Ajay Jaysingh Khopade
Subhas Balaram Bhowmick
N Arulsudar
Bhushan Shrikant Borole
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of AR082806A1 publication Critical patent/AR082806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica en la forma de una solución que comprende ingrediente insoluble en el agua con eficacia terapéutica y un análogo estructural similar del ingrediente activo insoluble en el agua, uno o más excipientes de aceptación farmacéutica y uno o más disolventes miscibles en el agua donde el ingrediente activo insoluble en el agua está presente en cantidades de eficacia terapéutica y el análogo estructural similar está presente en cantidades suficientes de tal modo que cuando se añade la composición a un vehículo acuoso, la misma forma una nanodispersión adecuada para infusión intravenosa donde dicha nanodispersión es estable durante períodos más largos en comparación con una dispersión formada a partir de una composición idéntica pero desprovista del análogo estructural similar del ingrediente activo insoluble en el agua.Reivindicación 4: Una composición farmacéutica de conformidad con la reivindicación 1, en el cual el ingrediente de actividad terapéutica insoluble en el agua es SN-38 y el análogo estructural similar es irinotecán. Reivindicación 6: Una composición farmacéutica de conformidad con la reivindicación 1, en la cual el ingrediente activo de actividad terapéutica insoluble en el agua es docetaxel y el análogo estructural similar es paclitaxel.
ARP110103162A 2010-08-30 2011-08-30 Composicion farmaceutica estable AR082806A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2180MU2010 2010-08-30

Publications (1)

Publication Number Publication Date
AR082806A1 true AR082806A1 (es) 2013-01-09

Family

ID=45773329

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103162A AR082806A1 (es) 2010-08-30 2011-08-30 Composicion farmaceutica estable

Country Status (3)

Country Link
AR (1) AR082806A1 (es)
TW (1) TW201215412A (es)
WO (1) WO2012029076A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3052101T3 (da) * 2013-10-04 2019-12-16 Prolynx Llc Konjugater af sn-38 med langsom frigivelse
WO2018037310A1 (en) * 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CA3087967A1 (en) 2018-01-12 2019-07-18 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
EP2252269A1 (en) * 2008-02-11 2010-11-24 Technion Research and Development Foundation, Ltd. Casein particles encapsulating therapeutically active agents and uses thereof
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
US20100203150A1 (en) * 2009-02-06 2010-08-12 National Tsing Hua University Novel amphiphilic copolymers and fabrication method thereof

Also Published As

Publication number Publication date
TW201215412A (en) 2012-04-16
WO2012029076A2 (en) 2012-03-08
WO2012029076A3 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
PE20150997A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
WO2011107749A3 (en) Pulsatile drug release
WO2011107755A3 (en) Immediate/delayed drug delivery
NZ702744A (en) D-amino acid compounds for liver disease
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
SV2011003907A (es) Composiciones antimicrobianas
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
UA118576C2 (uk) Фармацевтична композиція, яка містить бринзоламід
AR096854A1 (es) Composición farmacéutica para una liberación sostenida de lanreotide
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
AR082806A1 (es) Composicion farmaceutica estable
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
WO2012127277A3 (en) Bendamustine anionic-catioinic cyclopolysaccharide compositions
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2014043243A3 (en) Platinum compounds, compositions and methods for the treatment of cancer
IN2014DN10134A (es)
UY31669A1 (es) "formulación farmacéutica que comprende oxabispidinas /236"
JO3689B1 (ar) صيغ من الباراسيتامول قابلة للحقن
ES2530941T3 (es) Tratamiento y prevención de infección por el VIH
AR093414A1 (es) Composicion conservante que consiste en un complejo de oxicloro estabilizado y un poliol, y composicion topica que la comprende
AR110595A1 (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos
TH6662C3 (th) ยาฉีดเมลาโทนิน

Legal Events

Date Code Title Description
FB Suspension of granting procedure